Abstract |
Folate is essential for proliferating cells and folate transport pathways and folate-dependent metabolic processes show promise as targets for anti-neoplastic therapy. Folate receptor α (FOLR1), a folate transporter, is an attractive target for anti-neoplastic therapy due to its high affinity for folate, restricted range of expression in normal tissue and differential over-expression in malignant tissue. FOLR1 is expressed in non-small cell lung cancer, with a higher expression in adenocarcinoma compared with squamous cell carcinoma. Farletuzumab is a monoclonal antibody targeting FOLR1 which in pre-clinical studies led to cytotoxicity of FOLR1-expressing cells, inhibited tumor growth in animal models and showed limited reactivity with normal tissue. In phase I/II trials, farletuzumab was well tolerated as a single-agent and in combination, without additive toxicity with chemotherapy. An ongoing phase II, double blind, placebo-controlled study is evaluating farletuzumab in patients with FOLR1 expressing metastatic adenocarcinoma of lung.
|
Authors | Anish Thomas, Julia Maltzman, Raffit Hassan |
Journal | Lung cancer (Amsterdam, Netherlands)
(Lung Cancer)
Vol. 80
Issue 1
Pg. 15-8
(Apr 2013)
ISSN: 1872-8332 [Electronic] Ireland |
PMID | 23357463
(Publication Type: Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't, Review)
|
Copyright | Published by Elsevier Ireland Ltd. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- FOLR1 protein, human
- Folate Receptor 1
- farletuzumab
- Folic Acid
|
Topics |
- Animals
- Antibodies, Monoclonal, Humanized
(administration & dosage, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, genetics, metabolism)
- Clinical Trials as Topic
- Folate Receptor 1
(antagonists & inhibitors, genetics, metabolism)
- Folic Acid
(metabolism)
- Humans
- Lung Neoplasms
(drug therapy, genetics, metabolism)
|